Aurinia Pharmaceuticals Receives Buy Rating and Target Price of $17

Aurinia Pharmaceuticals (AUPH) has received a Buy rating and a $17 target price from H.C. Wainwright analyst Arthur He. The company's successful lupus nephritis franchise and solid financial health, including a 28.1% year-over-year revenue growth and 16.11% net margin, support this positive outlook. Aurinia's innovative product offerings and strategic focus on autoimmune diseases also contribute to its promising future.

Aurinia Pharmaceuticals (AUPH) has received a Buy rating and a $17 target price from H.C. Wainwright analyst Arthur He. The company's robust financial performance and strategic focus on autoimmune diseases have driven this positive outlook. Aurinia's successful lupus nephritis franchise and solid financial health, including a 28.1% year-over-year revenue growth and 16.11% net margin, support this rating [1].

Aurinia's innovative product offerings and strategic focus on autoimmune diseases also contribute to its promising future. The company's recent Phase 1 study results of aritinercept, an immunotherapy, demonstrate its commitment to advancing innovative therapies. Despite facing setbacks such as being dropped from several Russell indexes, Aurinia has pivoted to profitability, showcasing a notable increase in quarterly revenue and net income [1].

Aurinia is scheduled to announce its Q2 earnings results on Thursday, July 31st, with the consensus EPS estimate at $0.14 and revenue estimate at $64.27M (+12.4% Y/Y). Over the last 2 years, AUPH has beaten EPS estimates 88% of the time and revenue estimates 63% of the time [2].

The company's financial turnaround is underpinned by robust annual revenue growth projected at 12.2% and earnings growth forecast at 25.8%, outpacing broader market expectations. These figures underscore Aurinia's recovery trajectory and innovation prowess [1].

References:
[1] https://finance.yahoo.com/news/us-high-growth-tech-stocks-173820877.html
[2] https://seekingalpha.com/news/4474388-aurinia-pharma-q2-2025-earnings-preview